← Back to Search

FT500 for Breast Cancer

Phase 1
Waitlist Available
Research Sponsored by Fate Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 29 and every 8 weeks thereafter through day 366
Awards & highlights

Study Summary

This trial is testing a new cancer treatment that uses a person's own immune cells to attack their tumor. The hope is that this will be more effective than current treatments, and that it can be used in combination with other treatments to help people with advanced solid tumors.

Eligible Conditions
  • Breast Cancer
  • Liver Cancer
  • Solid Tumors
  • Non-Small Cell Lung Cancer
  • Melanoma
  • Small Cell Lung Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Microsatellite Instability
  • Neuroendocrine Carcinoma
  • Lymphoma
  • Kidney Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Stomach Cancer
  • Head and Neck Cancers
  • Squamous Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 29 and every 8 weeks thereafter through day 366
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 29 and every 8 weeks thereafter through day 366 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort.
Secondary outcome measures
Duration of FT500 persistence
Objective-response rate (ORR)

Trial Design

3Treatment groups
Experimental Treatment
Group I: FT500 in Combination with Immune Checkpoint InhibitorExperimental Treatment6 Interventions
FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.
Group II: FT500 MonotherapyExperimental Treatment3 Interventions
FT500 administered once weekly for 3 weeks as a monotherapy
Group III: FT500 +IL-2 in Combination with Immune Checkpoint InhibitorExperimental Treatment7 Interventions
FT500 + IL-2 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
FDA approved
Nivolumab
FDA approved
Atezolizumab
FDA approved
Aldesleukin
FDA approved
Pembrolizumab
FDA approved
Fludarabine
FDA approved
FT500
2019
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

Fate TherapeuticsLead Sponsor
21 Previous Clinical Trials
1,764 Total Patients Enrolled
1 Trials studying Breast Cancer
5 Patients Enrolled for Breast Cancer
Fate Trial DisclosureStudy DirectorFateTrialDisclosure@fatetherapeutics.com
10 Previous Clinical Trials
829 Total Patients Enrolled
1 Trials studying Breast Cancer
5 Patients Enrolled for Breast Cancer
Jeff Chou, MDStudy DirectorFate Therapeutics
4 Previous Clinical Trials
81 Total Patients Enrolled
1 Trials studying Breast Cancer
5 Patients Enrolled for Breast Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
2019. "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03841110.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top